Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative research agreement with Canada-based Telescope Innovations Corp. (CNSX: TELI). The financial details of the agreement have not been disclosed. The partnership aims to harness Telescope’s expertise in automation, robotics, and artificial intelligence (AI) to expedite the drug development process.
The collaboration will focus on the implementation of Self-Driving Laboratories (SDLs), an innovative AI-driven approach to chemical research that integrates advanced process analytical technology and is executed through robotic automation. Telescope’s SDLs have demonstrated the ability to optimize material properties and chemical synthesis methods at a pace up to 100 times faster than conventional research methods, potentially leading to significant reductions in the time and cost associated with the development of new pharmaceuticals.
Pfizer has previously collaborated with Telescope to establish the proof of concept for Telescope’s automation product for online chemistry analysis, DirectInject-LC. The new collaboration will involve the establishment of a joint steering committee by both companies to oversee the application of SDL technology in development projects and ensure its effective deployment.- Flcube.com
